Presentation is loading. Please wait.

Presentation is loading. Please wait.

경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실 2013.03.29.

Published byPearl Stone Modified over 8 years ago

Similar presentations

Presentation on theme: "경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실 2013.03.29."— Presentation transcript:

1 경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실 2013.03.29

2  2001 년 chronic hepatitis B, 09 년 부터 B-viral LC 로 본원 f/u  2011.2 HCC at S 6/7,8 -> 2011.3.18 TACE #1  2011.8.23 recurrent HCC at S5 -> RFA #1 2011.9.8  2011.11.1 liver abscess 로 입원 후 퇴원.  2013.3.20 Liver CT 상 right pleural mass or right paraspinal mass.  2013.3.20 PET CT Suggestive of neurogenic tumor, R/O Metastasis  토의 목적 : 향후 치료 방향 논의 History Case 1 12024069 윤 O 식 M/53 DM/HTN/TBc/Hepatitis(-/-/-/+) B-viral LC : 2001 년 진단. 2011.2 부터 entecavir 0.5mg 복용중 Op Hx (-) Alcohol Hx (-), Smoking Hx (-)

3 Underlying liver function and performance status CBC/DC WBC(mm 3 )6470 Hb(g/dl)14.8 PLT(mm 3 )164k PT(sec)13.4 INR1.00 Performance status: Grade 0 Chemistry TB/DB(mg/dL)0.57/- AST/ALT(IU/L)27/35 ALP/rGT(IU/L)67/48 Prot/Alb(g/dL)7.5/4.5 BUN/Cr(mg/dL)-/- LC & Stage Child-PughA (5) MELD score0.74 Esophageal varices- Ascites- Encephalopathy- 12024069 윤 O 식 M/53 Case 1 Tumor markers AFP (ng/mL)6.63 CEA (ng/mL) - PIVKA II (mAU/mL)53 CA19-9 - Viral markers/ underlying liver disease HBV / HCV(+/-) HBeAg / HBeAb(-/+) Virus titer0 IU/mL Antiviral Txentecavir 0.5mg Alcohol(-)

4 2001 11.02 11.08 11.11 13.03 TACE #1 (2011.3.18) TACE #1 (2011.3.18) HCC S 6/7,8 *Liver –TACE CT (2013.3.20) : Increased size of right pleural mass or right paraspinal mass. 1. metastasis, 2. neurogenic tumor with rapid growing --> malignant lesion is more likely. No change of fibrotic scarring after RFA at segment 8/5. No change of FNH like nodules at segment 7 and segment 4. Liver cirrhosis with multiple regenerating nodules and dysplastic nodules 10259334 조 O 복 F/57 B-viral LC B-viral LC RFA#1 (2011.9.8) RFA#1 (2011.9.8) recurrent HCC Liver abscess Case 1 Tumor Stage and Clinical Course 12024069 윤 O 식 M/53 Rt.paraspinal mass 11 년 11 월 12 년 03 월 12 년 06 월 12 년 09 월 12 년 12 월 13 년 3 월 AFP 7.7310.028.288.185.846.63 PIVKA Ⅱ 242053-- PET (2013.03.20) No abnormal hypermetabolic lesion suggesting recurrence in liver Hypermetabolic lesion in right paravertebral space and adjacent T12 body : Suggestive of neurogenic tumor R/O Metastasis

5 Summary – 치료 방침 결정 12024069 윤 O 식 M/53 Case 1 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial tumor stage Date: Modified UICC ( 대한간암연구학회 ) T 2, N 0, M 0 Stage: II BCLC Very early/Early/ Intermediate / Advanced Current status Locally advanced with Well preserved liver function Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number 1 Repeated TACE ( 1 회 / 기간 ) Y Vascular or bile duct invasion N High uptake of PET N High AFP or PIVKA II N Not normalized AFP after curative Tx N Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N

6  2008 년 Alcoholic LC c ehophageal varix, 본원 IG f/u  Abdominal distention 및 diarrhea 증세로 2013.3.14 소화기 내과 입원  2013.3.15 Liver CT : - HCCs at S5, S7 and left lateral segment - Portal vein, splenic vein, and superior mesenteric vein thrombosis.  TACE indication 되지 않아 Tomo Tx 시행 예정. 향후 치료 방향 논의 History Case 2 10259334 유 O 조 F/57 DM/HTN/TBc/Hepatitis(-/-/-/-) Op Hx (+) : 01’ appendectomy, 09’ kyphosis OP Alcohol Hx (+), Smoking Hx (+) ex smoker : 10 갑년

7 Underlying liver function and performance status CBC/DC WBC(mm 3 )2440 Hb(g/dl)11.8 PLT(mm 3 )57k PT(sec)19.9 INR1.72 Performance status: Grade 0 Chemistry TB/DB(mg/dL)1.65/0.97 AST/ALT(IU/L)86/40 ALP/rGT(IU/L)145/219 Prot/Alb(g/dL)6.5/3.1 BUN/Cr(mg/dL)12/0.8 LC & Stage Child-PughB (8) MELD score12.26 Esophageal varicesCb F2 Li-m RC++ Ascites2 Encephalopathy- 10259334 유 O 조 F/57 Case 2 Tumor markers AFP (ng/mL)232 CEA (ng/mL) - PIVKA II (mAU/mL)- CA19-9 - Viral markers/ underlying liver disease HBV / HCV(-/-) HBeAg / HBeAb(-/-) Virus titer0 IU/mL Antiviral Tx- Alcohol(+)

8 Tumor Stage and Clinical Course 08 11.03 13.03 Case 2 Esophageal varix EVL x9 10259334 유 O 조 F/57 Alcoholic LC *Liver MR (2013.03.22) : Variable sized, multiple HCC at the liver both lobes. with tumor thrombosis at right, left portal vein. with thrombosis in main portal vein, splenic vein, SMV. Liver CT : HCCs at S5, S7 and left lateral segment. Portal vein, splenic vein, superior mesenteric vein thrombosis. PET (2013.03.21) HCCs in segment 5 and left lateral segment No abnormal hypermetabolic lesion suggesting distant metastasis Underlying liver cirrhosis with ascites

9 Summary – 치료 방침 결정 10259334 유 O 조 F/57 Case 2 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial tumor stage Date: Modified UICC ( 대한간암연구학회 ) T 4, N 0, M 0 Stage: VI BCLC Very early/Early/ Intermediate / Advanced Current status Locally advanced HCC with Compensated (risk of decompensation) Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation Y Tumor number 2 Repeated TACE ( 2 회 / 기간 ) N Vascular or bile duct invasion Y High uptake of PET Y High AFP or PIVKA II Y Not normalized AFP after curative Tx N Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease -

10  2009 년 C-viral LC 진단  HCC at S4 - > 2009.07.27 TACE #1  Marginal reccurred HCC, S4 -> 2010.01.05 TACE #2  Marginal recurrence, small nodular HCC (S7) -> 2010.04.20 TACE #3  Recurrent (S4) & new (S7/8) HCC -> 2011.07.27 TACE #4  Marginal recurrence, S7/8 -> 2012.04.16 TACE #5  Viable tumor(S4/8), marginal recurrence(S7),HCC(S8) -> 2012.07.23 TACE #6  Suggestive of recurrent HCC in junction of S4/8-> 2012.12.20 TACE #7  recurred HCC S4/8 -> 2013.03.26 TACE #8 향후 치료 방향 논의 History Case 3 10592087 김 O F/73 DM/HTN/TBc/Hepatitis(-/-/-/+) C-viral LC : 2009 년 진단.., Hypothyroidism 으로 Synthyroxine 0.1mg 복용중. Op Hx (-) Alcohol Hx (-), Smoking Hx (-)

11 Underlying liver function and performance status CBC/DC WBC(mm 3 )3690 Hb(g/dl)11.2 PLT(mm 3 )78k PT(sec)14.4 INR1.13 Performance status: Grade 0 Chemistry TB/DB(mg/dL)0.85/0.5 AST/ALT(IU/L)74/31 ALP/rGT(IU/L)133/91 Prot/Alb(g/dL)5.9/2.9 BUN/Cr(mg/dL)12/0.5 LC & Stage Child-PughA(6) MELD score4.2 Esophageal varices(-) Ascites- Encephalopathy- 10592087 김 O F/73 Case 3 Tumor markers AFP (ng/mL)213 CEA (ng/mL) 4.61 PIVKA II (mAU/mL)- CA19-9 38.61 Viral markers/ underlying liver disease HBV / HCV(-/+) HBeAg / HBeAb(- / -) Virus titer- Antiviral Tx- Alcohol(-)

12 2009 09.07 10.01 10.04 11.07 12.04 12.07 TACE #1 (2009.7.27) TACE #1 (2009.7.27) HCC (S4) 10259334 조 O 복 F/57 C-viral LC C-viral LC TACE #2 (2010.01.05) TACE #2 (2010.01.05) TACE #3 (2010.04.20) TACE #3 (2010.04.20) Case 3 Tumor Stage and Clinical Course 10592087 김 O F/73 10 년 01 월 11 년 06 월 12 년 03 월 12 년 09 월 12 년 12 월 13 년 3 월 AFP 29464253212213 PIVKA Ⅱ 135219158- HCC (S4) HCC (S7) HCC (S4.7) TACE #4 (2011.07.27) TACE #4 (2011.07.27) TACE #5 (2012.04.16) TACE #5 (2012.04.16) TACE #6 (2012.7.23) TACE #6 (2012.7.23) 12.12 13.03 HCC (S7/8) HCC (S4/8) TACE #7 (2012.12.20) TACE #7 (2012.12.20) TACE #8 (2013.03.26) TACE #8 (2013.03.26) PET (2013.03.21) No abnormal hypermetabolic lesion in lipiodolized HCC of segment 4/8 Post-TACE state in segment 4

13 Summary – 치료 방침 결정 10592087 김 O F/73 Case 3 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial tumor stage Date: Modified UICC ( 대한간암연구학회 ) T 2, N 0, M 0 Stage: II BCLC Very early/Early/ Intermediate / Advanced Current status Locally advanced HCC with well preserved liver function and low-risk for recurrence Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number 2 Repeated TACE ( 2 회 / 기간 ) Y Vascular or bile duct invasion N High uptake of PET N High AFP or PIVKA II Y Not normalized AFP after curative Tx N Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease -

14  2012.6 epigastric pain 으로 대구 파티마 병원 내원, - B-viral LC, r/o HCC (segment 5~8 8x6 cm) 진단  HCC at Rt lobe -> TACE#1 (2012.7.17)  HCC at S8,S5 -> TACE #2 (2012.8.28)  HCC at S8,S5 -> TACE #3 (2012.10.5)  HCC at S8,S5 ->TACE #4 (2012.12.5)  2013.1.29 S4,5,8 sectionectomy  2013.2.24 chemo Tx (5-FU, 1-VL) 1 차  토의 목적 : 향후 치료 방향 논의 History Case 4 12288861 홍 O 선 M/44 DM/HTN/TBc/Hepatitis(-/-/-/+) B-viral LC : 2012.6 진단 Entecavir 0.5mg 복용중 Op Hx (+) 2013.1.29 S4,5,8 sectionectomy Alcohol Hx (+), Smoking Hx (+) ex somker 20 갑년

15 Underlying liver function and performance status CBC/DC WBC(mm 3 )7870 Hb(g/dl)15.6 PLT(mm 3 )309k PT(sec)12 INR0.88 Performance status: Grade 0 Chemistry TB/DB(mg/dL)0.75/0.57 AST/ALT(IU/L)41/26 ALP/rGT(IU/L)136/169 Prot/Alb(g/dL)7.7/4.4 BUN/Cr(mg/dL)9/0.7 LC & Stage Child-PughA (5) MELD score0.83 Esophageal varices- Ascites- Encephalopathy- 12288861 홍 O 선 M/44 Case 4 Tumor markers AFP (ng/mL)119 CEA (ng/mL) - PIVKA II (mAU/mL)>2000 CA19-9 - Viral markers/ underlying liver disease HBV / HCV(+/-) HBeAg / HBeAb(-/+) Virus titer34 IU/mL Antiviral Txentecavir 0.5mg Alcohol(+)

16 12.06 12.07 12.08 12.10 12.12 13.01 13.02 TACE #1 (2012.7.17) TACE #1 (2012.7.17) HCC S 5,8 10259334 조 O 복 F/57 B-viral LC HCC S5,S8 B-viral LC HCC S5,S8 Case 4 Tumor Stage and Clinical Course 12288861 홍 O 선 M/44 12 년 07 월 12 년 08 월 12 년 12 월 13 년 2 월 AFP 119.628.2918.9311.37 PIVKA Ⅱ >2000-- PET (2013.01.03) Known HCC : No abnormal hypermetabolic lesion in the liver. No abnormal activity suggesting metastasis. No abnormal hypermetabolic lesion suggesting malignancy.. HCC S 5,8 TACE #2 (2012.8.28) TACE #2 (2012.8.28) HCC S 5,8 TACE #3 (2012.10.5) TACE #3 (2012.10.5) HCC S 5,8 TACE #4 (2012.12.5) TACE #4 (2012.12.5) OP S4,5,8 sectionectomy S4,5,8 sectionectomy Chemo Tx

17 Summary – 치료 방침 결정 12288861 홍 O 선 M/44 Case 4 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial tumor stage Date: Modified UICC ( 대한간암연구학회 ) T 3, N 0, M 0 Stage: III BCLC Very early/Early/ Intermediate / Advanced Current status Locally advanced with Well preserved liver function Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number 2 Repeated TACE ( 1 회 / 기간 ) Y Vascular or bile duct invasion N High uptake of PET N High AFP or PIVKA II N Not normalized AFP after curative Tx N Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N

Download ppt "경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실 2013.03.29."

Similar presentations

Intermediate stage HCC management

Intermediate stage HCC management
Staging Strategy and Treatment for Patients With HCC

Staging Strategy and Treatment for Patients With HCC
An update on liver transplantation Joint Hospital Surgical Grand Round 19/7/2014.

An update on liver transplantation Joint Hospital Surgical Grand Round 19/7/2014.
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer in the world and the third most common cause of cancer mortality.

Hepatocellular carcinoma (HCC) is the fifth most frequent cancer in the world and the third most common cause of cancer mortality.
WY Chu, Surgery, Tuen Mun Hospital, NTWC.  Initial management as a HST in rupture HCC.

WY Chu, Surgery, Tuen Mun Hospital, NTWC.  Initial management as a HST in rupture HCC.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Ayman Abdo MD, AmBIM, FRCPC

Ayman Abdo MD, AmBIM, FRCPC
Biliary Tumors Cholangiocarcinoma and Cancer of the Gall Bladder

Biliary Tumors Cholangiocarcinoma and Cancer of the Gall Bladder
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.

© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
Epidemiology  Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.  Worldwide, its prevalence follows that of hepatitis B.

Epidemiology  Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.  Worldwide, its prevalence follows that of hepatitis B.
HEPATOCELLULAR CARCINOMA Monton. HCC in Thailand Most common cancer in Thai male Incidence 5 x 100,000 / year Male : female = 3-8:1 Age > 40 yr.

HEPATOCELLULAR CARCINOMA Monton. HCC in Thailand Most common cancer in Thai male Incidence 5 x 100,000 / year Male : female = 3-8:1 Age > 40 yr.
Chronic liver disease Cirrhosis hepatic Encephalopathy Dr. Yasir M Khayyat MBcHB,FRCPC,FACP,ABIM Assistant professor of Medicine Faculty of Medicine Umm.

Chronic liver disease Cirrhosis hepatic Encephalopathy Dr. Yasir M Khayyat MBcHB,FRCPC,FACP,ABIM Assistant professor of Medicine Faculty of Medicine Umm.
Guzman, Alexander Joseph Hipolito, April Lorraine

Guzman, Alexander Joseph Hipolito, April Lorraine
Diagnosis of HCC History & PE Serologic Assays Radiology

Diagnosis of HCC History & PE Serologic Assays Radiology
Hepatocellular Carcinoma (HCC). Definition : Hepatocellular carcinoma is a primary malignancy of the hepatocyte, also known as liver cell carcinoma. Types.

Hepatocellular Carcinoma (HCC). Definition : Hepatocellular carcinoma is a primary malignancy of the hepatocyte, also known as liver cell carcinoma. Types.
Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.

Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.
HEPATIC TUMORS Dr.Cengiz Pata Gastroenterology Department Yeditepe University,Istanbul.

HEPATIC TUMORS Dr.Cengiz Pata Gastroenterology Department Yeditepe University,Istanbul.
HCC Guidelines 2011 1.

HCC Guidelines
SYB Case #2 Jordan Torok Class of 2010 December 11 th, 2008.

SYB Case #2 Jordan Torok Class of 2010 December 11 th, 2008.
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.

Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.

Similar presentations

Ads by Google